CCA
SAGE

Childress Capital Advisors’s Sage Therapeutics SAGE Stock Holding History

Childress Capital Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-65
Closed -$6K – 798
2020
Q4 		$6K Buy
+65
New +$4.79K ﹤0.01% 717

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Childress Capital Advisors's SAGE Position: Q1 2021 in Review

Childress Capital Advisors sold out of Sage Therapeutics (SAGE) in Q1 2021, closing a stake of 65 shares — an estimated $6K sold.

Childress Capital Advisors first reported a position in SAGE in Q4 2020 and held it in 1 quarter. The position peaked at $6K in Q4 2020. 262 funds tracked by Wall St. Rank hold SAGE as of Q1 2021.

  • Childress Capital Advisors reported no remaining Sage Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Childress Capital Advisors sold 65 Sage Therapeutics shares in Q1 2021, an estimated $6K.
  • Childress Capital Advisors first reported a position in Sage Therapeutics in Q4 2020 and held it in 1 quarter.
  • Childress Capital Advisors's Sage Therapeutics position peaked at $6K in Q4 2020.
  • 262 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2021.

Based on Childress Capital Advisors's 13F filing for Q1 2021, filed 21 May 2021.